The companies expect that the deal ‘that will facilitate accelerated development of more than 20 generic injectable products – including anti-infectives, oncolytics and cardiovascular medicines’.

The collaboration builds upon Baxter’s pending acquisition of Claris and its ScinoPharm collaboration. The partnership also ‘extends Baxter’s growing pipeline of generic injectables, further strengthening our portfolio with a broad range of high quality essential medicines’, according to Baxter’s President of Pharmaceuticals, Robert Felicelli. Although Baxter already manufactures a range of essential generic injectables, it expects this deal to ‘advance Baxter’s strategy of becoming a leader in generic injectables’.

In February 2017, Baxter announced its acquisition of India’s Claris Injectables. The acquisition of Claris, which is expected to close in the second half of 2017, will bring a portfolio of essential generics, including anaesthetics and analgesics, renal, anti-infectives and critical care medicines [1]. Baxter has also made a deal with Taiwan-based active pharmaceutical ingredient (API) maker ScinoPharm to develop, manufacture and commercialize five generic injectables used in cancer treatment, with an option to add up to 15 additional injectable molecules.

Baxter estimates that the global sterile generic injectables segment is worth more than US$40 billion, with a compound annual growth rate of approximately 10% (2010−2015).

Related articles
Baxter and Coherus amend biosimilar etanercept collaboration

Baxter and Coherus to collaborate on biosimilars

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Baxter expands injectables portfolio with purchase of Claris Injectables [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Jun 23]. Available from: www.gabionline.net/Pharma-News/Baxter-expands-injectables-portfolio-with-purchase-of-Claris-Injectables

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.